Literature DB >> 181595

Cytomegalovirus proteins. I. Polypeptides of virions and dense bodies.

M Fiala, R W Honess, D C Heiner, J W Heine, J Murnane, R Wallace, L B Guze.   

Abstract

Cytomegalovirus virions and dense bodies were purified by sucrose velocity and equilibrium centrifugation from the medium of fibroblasts infected with the strain AD169. The final virus preparations were purified more than 228-fold with respect to cellular proteins as determined by double-isotopic labeling and at least 1,600-fold on the basis of changes in the ratio of total protein to virus particles. The protein content of purified particles approximated that found for purified preparations of other herpesviruses. Twenty polypeptides ranging from 22,000 to greater than 230,000 molecular weight were detected in purified virus preparations by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Polypeptides of virions and dense bodies were allocated on the basis of analyses of preparations containing differing percentages of virions and dense bodies. Six polypeptides were represented predominantly or exclusively in virions, and four polypeptides were represented predominantly or exclusively in dense bodies, whereas the remainder appeared to be shared by both types of particles. Four polypeptides were glycosylated, and at least three of these appeared to be shared by both particles. Four polypeptides were glycosylated, and at least three of these appeared to be shared by both particle types. The protein composition of cytomegalovirus differs profoundly from that of herpes simplex virus.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 181595      PMCID: PMC354852     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Amino acid metabolism in mammalian cell cultures.

Authors:  H EAGLE
Journal:  Science       Date:  1959-08-21       Impact factor: 47.728

2.  INFECTIOUS PULMONARY DISEASE IN PATIENTS RECEIVING IMMUNOSUPPRESSIVE THERAPY FOR ORGAN TRANSPLANTATION.

Authors:  R B HILL; D T ROWLANDS; D RIFKIND
Journal:  N Engl J Med       Date:  1964-11-12       Impact factor: 91.245

3.  DISC ELECTROPHORESIS. II. METHOD AND APPLICATION TO HUMAN SERUM PROTEINS.

Authors:  B J DAVIS
Journal:  Ann N Y Acad Sci       Date:  1964-12-28       Impact factor: 5.691

4.  DISC ELECTROPHORESIS. I. BACKGROUND AND THEORY.

Authors:  L ORNSTEIN
Journal:  Ann N Y Acad Sci       Date:  1964-12-28       Impact factor: 5.691

5.  Serologic differentiation of viruses responsible for cytomegalic inclusion disease.

Authors:  T H WELLER; J B HANSHAW; D E SCOTT
Journal:  Virology       Date:  1960-09       Impact factor: 3.616

6.  An improved periodic acid fuchsin sulfite staining method for evaluation of glycoproteins.

Authors:  W F McGUCKIN; B F McKENZIE
Journal:  Clin Chem       Date:  1958-12       Impact factor: 8.327

7.  Isolation of intranuclear inclusion producing agents from infants with illnesses resembling cytomegalic inclusion disease.

Authors:  J M CRAIG; J C MACAULEY; T H WELLER; P WIRTH
Journal:  Proc Soc Exp Biol Med       Date:  1957-01

8.  Cytopathogenic agent resembling human salivary gland virus recovered from tissue cultures of human adenoids.

Authors:  W P ROWE; J W HARTLEY; S WATERMAN; H C TURNER; R J HUEBNER
Journal:  Proc Soc Exp Biol Med       Date:  1956-06

9.  The morphogenesis of human cytomegalovirus. Isolation and polypeptide characterization of cytomegalovirions and dense bodies.

Authors:  I Sarov; I Abady
Journal:  Virology       Date:  1975-08       Impact factor: 3.616

10.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

View more
  23 in total

1.  Synthesis of proteins and glycoproteins in cells infected with human cytomegalovirus.

Authors:  M F Stinski
Journal:  J Virol       Date:  1977-09       Impact factor: 5.103

Review 2.  The murine cytomegalovirus as a model for the study of viral pathogenesis and persistent infections.

Authors:  J B Hudson
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

3.  Proteins associated with purified human cytomegalovirus particles.

Authors:  C J Baldick; T Shenk
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

Review 4.  Molecular biology and immunology of cytomegalovirus.

Authors:  P D Griffiths; J E Grundy
Journal:  Biochem J       Date:  1987-01-15       Impact factor: 3.857

5.  Synthesis and processing of the envelope gp55-116 complex of human cytomegalovirus.

Authors:  W J Britt; D Auger
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

6.  Molecular cloning and analysis of three cDNA clones homologous to human cytomegalovirus RNAs present during late infection.

Authors:  J Martinez; S C St Jeor
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

7.  Highly acidic C-terminal region of cytomegalovirus pUL96 determines its functions during virus maturation independently of a direct pp150 interaction.

Authors:  Teal M Brechtel; Edward S Mocarski; Ritesh Tandon
Journal:  J Virol       Date:  2014-02-05       Impact factor: 5.103

8.  Pattern of anti-cytomegalovirus IgM antibodies determined by immunoblotting. A study of kidney graft recipients developing a primary or recurrent CMV infection.

Authors:  J Basson; J C Tardy; M Aymard
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

9.  Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies.

Authors:  Thomas J Gardner; Cynthia Bolovan-Fritts; Melissa W Teng; Veronika Redmann; Thomas A Kraus; Rhoda Sperling; Thomas Moran; William Britt; Leor S Weinberger; Domenico Tortorella
Journal:  Clin Vaccine Immunol       Date:  2013-02-06

10.  Cloning and physical mapping of a gene fragment coding for a 64-kilodalton major late antigen of human cytomegalovirus.

Authors:  H Pande; S W Baak; A D Riggs; B R Clark; J E Shively; J A Zaia
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.